Hims & Hers Stock Risks After Novo Nordisk Partnership Termination

Hims & Hers Stock Concerns

• 🎯 Herb Greenberg flagged Hims & Hers stock as high-risk, describing it as a "smug and senseless" investment driven by investor enthusiasm rather than fundamentals.
• ⚠️ Despite the stock doubling since his initial red flag in February, the core risks remain, particularly concerning its business model.

Core Business and Weight Loss Drugs

• 💊 Hims & Hers has historically relied on drugs for erectile dysfunction and baldness.
• 📈 The company's significant growth has recently been driven by weight loss drugs, which now constitute over 50% of its business.
• ⚠️ This segment operates in a gray area by compounding a patented drug through personalization and micro-dosing, a practice that has drawn scrutiny.

Novo Nordisk Partnership Termination

• 🚫 Novo Nordisk has accused Hims & Hers of deceptive marketing and terminated their partnership.
• 📉 This termination poses a significant risk, especially if the practice of compounding weight loss drugs is curtailed or eliminated.
• 📉 The company's core business, excluding weight loss drugs, has been showing signs of deceleration.

Investment Outlook

• ⚡ The stock's recent 30% crash highlights its vulnerability to such events, illustrating the principle of "live by the squeeze, die by the squeeze."
• 🔍 The surprise termination by Novo Nordisk, a partner from just a month prior, underscores the unpredictable nature of these risks.